(IN BRIEF) Sanofi reported new real-world evidence showing that immunization with Beyfortus can significantly reduce RSV-related hospitalizations not only during an infant’s first RSV season but also into the second year of life. The NIRSE-GAL study in Galicia, Spain, demonstrated … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Retail, Science, Security & Safety, Technology
Tagged Beyfortus, early lung protection, Federico Martinón Torres, Galicia Spain, hospitalization reduction, infant immunization, infant respiratory health, lower respiratory tract infection, monoclonal antibody, New Published Data Reinforce Value of Universal Infant RSV Immunization in Reducing Hospital Burden, NIRSE GAL study, nirsevimab, pediatric prevention, public health strategy, real-world evidence, RSV respiratory syncytial virus, RSVVW 26 Rome, Sanofi, The Lancet Infectious Diseases, Thomas Triomphe
(IN BRIEF) Sanofi has launched early global shipments of Beyfortus (nirsevimab) in anticipation of the 2025–2026 RSV season, enabling healthcare providers to begin immunizations well before the typical onset of infections in November. In collaboration with AstraZeneca, Sanofi has significantly … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AstraZeneca, Beyfortus, EU label, extended protection, global distribution, hospitalizations, infant immunization, lower respiratory tract disease, monoclonal antibody, newborn care, nirsevimab, pediatric health, public health, real-world studies, respiratory syncytial virus, RSV, RSV season, Sanofi, Thomas Triomphe, Vaccine Innovation, vaccine supply chain
(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, News, Pharma & Biotech
Tagged AstraZeneca, Beyfortus, commercialization, contractual agreements, nirsevimab, partnership, Sanofi, Sobi, USA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?